Fortress Biotech Earnings Call Transcripts
Fiscal Year 2025
-
Q3 2025 saw 21% revenue growth, led by Emrosi's strong launch and rapid prescription uptake. Gross margin improved sequentially, adjusted EBITDA turned positive, and the company expects sustainable EBITDA positivity in Q4. Emrosi is projected to become a leading rosacea therapy.
-
The meeting confirmed a quorum, introduced directors and advisors, and presented five motions for shareholder vote. All director nominees, auditor ratification, and executive compensation proposals passed, while the officer exculpation amendment was not approved.
Fiscal Year 2024
-
2024 revenue met guidance at $56M, with IMROCI FDA-approved and set for launch in early 2025. IMROCI is expected to drive significant growth, with payer coverage ramping over 12–18 months and strong interest from physicians and payers.